FDA Approves Rybrevant (amivantamab-vmjw) as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

FDA Approves Rybrevant (amivantamab-vmjw) as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of Rybrevant (amivantamab-vmjw) for the… Read More »

How Long Does it Take for Botox to Work? 11 FAQs

Botox treatment for crow’s feet, forehead, and in between the eyebrows has hiked in popularity in the past decade, particularly in the last year. One reason for this has to be the increasing popularity of online dating and meeting apps that have put our faces on the display more than ever before. This article talks… Read More »